Malaria Clinical Trial
Official title:
Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné
IPTi, a strategy whereby infants are provided treatment doses of antimalarials at routine
vaccination visits, has been shown to significantly reduce malaria and anemia in two studies
in Tanzania. However the results obtained in Gabon are not similar. Many factors are likely
to influence the efficacy or effectiveness IPTi. It is reasonable to assume that the
efficacy of IPTi will be influenced markedly by the sensitivity of Plasmodium falciparum to
the antimalarial drug (Sulfadoxine-Pyrimethamine) used for IPTi.
In order to interpret the results of individual IPTi trials conducted by the IPTi
Consortium, and to provide information for policy makers regarding the predicted efficacy of
IPTi, it is essential to obtain information on antimalarial drug sensitivity of
Sulfadoxine-Pyrimethamine now that the IPTi trial has been conducted. The simplest and most
universally accepted measure of testing for antimalarial drug efficacy is the "in vivo
efficacy study," which follows a standardized World Health Organization protocol.
A second reason for evaluating drug resistance as an adjunct to the IPTi trials is to
determine if the intervention increases the carriage and/or spread of drug resistant P.
falciparum parasites.
Thirdly the overall effect at the community level of selection of resistant genotypes in
IPTi-recipients is unclear.
Administration of standard single oral dose of sulfadoxine-pyrimethamine to children aged
6-59 month old children in Lambaréné at enrolment, if eligible according to the approved
protocol.
139 subjects will be enrolled and treated with Sulfadoxine-Pyrimethamine for uncomplicated
malaria. Thereafter each subject will be followed according to the approved protocol
The proportion of subjects with Adequate Clinical and Parasitological response (ACPR) by day
28, Early Treatment Failure (ETF), Late Clinical Failure (LCF) and Late Parasitological
Failure (LPF)will be evaluated.
secondly the frequency of molecular markers for Sulfadoxine-Pyrimethamine drug resistance
will be determined.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |